Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for REC-617 in Solid tumor/s, Cancer. The expected timing is based on the latest available company guidance and may change.
ELUCIDATE trial. 12/9/24- Reported interim Ph1 data. Plans to continue monotherapy dose escalation and initiate combination studies in H1 2025. 8/5/25- Additional monotherapy data in H2 2025. 11/05/25:- Updated Ph1 monotherapy data established MTD with manageable safety and early anti-tumor activity. ELUCIDATE expanded into PROC with ongoing Ph2 monotherapy cohort and initiated Ph1 combination arm. 02/25/26:- REC-617 showed promising Ph1/2 safety and efficacy. Early Ph1 combo safety and PK data expected in H1 2027. 05/06/26:- Early ELUCIDATE Ph1 combo safety and PK data reiterated for H1 2027. 08/05/26:- Early Ph1 combination safety and PK data reiterated for H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.